Melatonin modulates signal transduction pathways and apoptosis in experimental colitis

Journal of Pineal Research

Volumn 41, Issue 4, 2006, Pages 363-373

  Mazzon, Emanuela ^a,b   Esposito, Emanuela ^c   Crisafulli, Concetta ^a   Riccardi, Luisa ^c   Muià, Carmelo ^a   Bella, Paolo Di ^b   Meli, Rosaria ^c   Cuzzocrea, Salvatore ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Apoptosis; Colon damage; DNBS; Free radicals; Inflammation

Indexed keywords

DINITROBENZENESULFONIC ACID; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELATONIN; PROTEIN BCL 2; SULFONIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COLITIS; CONTROLLED STUDY; ENZYME ACTIVATION; MALE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; COLITIS; CYTOKINES; DINITROFLUOROBENZENE; DISEASE MODELS, ANIMAL; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MELATONIN; PHOSPHOSERINE; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33749365523     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2006.00378.x     Document Type: Article

References (65)

1. ROMAGNANI S. Th1/Th2 cells. Inflamm Bowel Dis 1999; 5:285-294.
2. GROUX H, O'GARRA A, BIGLER M. A CD4 T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737-742.
3. COTTREZ F, HURST SD, COFFMAN RL, GROUX H. T-regulatory cells 1inhibit a Th2-specific response in vivo. J Immunol 2000; 165:4848-4853.
4. BUTCHER EC, PICKER LJ. Lymphocyte homing and homeostasis. Science 1996; 272:60-66.
5. PAPADAKIS KA, TARGAN SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000; 119:1148-1157.
6. BARNES PJ, KARIN M. Nuclear factor-B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336:1066-1071.
7. PARKS DA. Oxygen radicals: mediators of gastrointestinal pathophysiology. Gut 1989; 30:293-298.
8. KITAHARA T, SUZUKI K, ASAKURA H et al. Active oxygen species generated monocytes and polymorphnuclear cells in Crohn's disease. Dig Dis Sci 1988; 33:951-955.
9. VERSPAGET H, BEEKEN W. Mononuclear phagocytes in the gastrointestinal tract. Acta Chir Scand 1985; 25:113-126.
10. SHAULIAN E, KARIN M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4:E131-E136.
11. CUZZOCREA S, RILEY DP, CAPUTI AP, SALVEMINI D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 2001; 53:135-159.
12. TAN DX, CHEN LD, POEGGELLER B, MANCHESTER LC, REITER RJ. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocrine J 1993; 1:57-60.
13. REITER RJ. Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB J 1995; 9:526-533.
14. ALLEGRA M, REITER RJ, TAN DX, GENTILE C, TESORIERE L, LIVREA MA. The chemistry of melatonin's interaction with reactive species. J Pineal Res 2003; 34:1-10.
15. WINIARSKA K, FRACZYK T, MALINSKA D, DROZAK J, BRYLA J. Melatonin attenuates diabetes-induced oxidative stress in rabbits. J Pineal Res 2006; 40:168-176.
16. GILAD E, CUZZOCREA S, ZINGARELLI B, SALZMAN AL, SZABÒ C. Melatonin is a scavenger of peroxinitrite. Life Sci 1997; 60:169-174.
17. CUZZOCREA S, ZINGARELLI B, GILAD E, HAKE P, SALZMAN AL, SZABÒ C. Protective effect of melatonin in carrageenan-induced models of local inflammation. J Pineal Res 1997; 23:106-116.
18. CUZZOCREA S, TAN DX, COSTANTINO G, MAZZON E, CAPUTI AP, REITER RJ. The protective role of endogenous melatonin in carrageenan-induced pleurisy in the rat. FASEB J 1999; 13:1930-1938.
19. CUZZOCREA S, MAZZON E, SERRAINO I et al. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J Pineal Res 2001; 30:1-12.
20. FRIES W, MAZZON E, SQUARZONI S et al. Experimental colitis increases small intestine permeability in the rat. Lab Invest 1999; 79:49-57.
21. WALLACE JL, KEENAN CM, GALE D, SHOUPE TS. Exacerbation of experimental colitis by non-steroidal antinflammatory drugs is not related to elevate leukotriene B4 synthesis. Gastroenterology 1992; 102:18-27.
22. MILLER MJ, THOMPSON JH, ZHANG XJ et al. Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis. Gastroenterology 1995; 109:1475-1483.
23. ZINGARELLI B, SQUADRIT OF, GRAZIANI P, CAMERINI R, CAPUTI AP. Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats. Agents Actions 1993; 39:150-156.
24. DIAZ-GRANADOS N, HOWE K, LU J, MCKAY DM. Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am J Pathol 2000; 156:2169-2177.
25. CUZZOCREA S, MAZZON E, DUGO L, CAPUTI AP, RILEY DP, SALVEMINI D. Protective effects of M40403, a superoxide dismutase mimetic, in a rodent model of colitis. Eur J Pharmacol 2001; 432:79-89.
26. GRISHAM MB. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994; 344:859-861.
27. RACHMILEWITZ D, STAMLER JS, KARMELI F et al. Peroxynitrite-induced rat colitis - a new model of colonic inflammation. Gastroenterology 1993; 105:1681-1688.
28. SIMMONDS NJ, ALLEN RE, STEVENS TR, VAN SOMEREN RN, BLAKE DR, RAMPTON DS. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology 1992; 1:186-196.
29. MCKENZIE SJ, BAKER MS, BUFFINTON GD, DOE WF. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J Clin Invest 1996; 98:136-141.
30. BECKMAN JS, BECKMAN TW, CHEN J, MARSHALL PA, FREEMAN BA. Apparent hydroxyl radical production by peroxynitrite: implication for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87:1620-1624.
31. ISCHIROPOULOS H, ZHU L, BECKMAN JS. Peroxynitrite formation from macrophage-derived nitric oxide. Arch Biochem Biophys 1992; 298:446-451.
32. SZABO C, DAWSON VL. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci 1998; 19:287-298.
33. ZINGARELLI B, SZABÒ C, SALZMAN AL. Blockade of poly (ADP-ribose) synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in murine colitis. Gastroenterology 1999; 116:335-345.
34. SZABO C, LIM LH., CUZZOCREA S et al. Inhibition of poly (ADP-ribose) synthetase exerts anti-inflammatory effects and inhibits neutrophil recruitment. J Exp Med 1997; 186:1041-1049.
35. SZABO C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett 2003; 140-141:105-112.
36. HADDAD JJ. Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cell Signal 2002; 14:879-897.
37. SCHRECK R, RIEBER P, ABAEUERLE PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 1991; 10:247-258.
38. BYUN MS, JEON KI, CHOI JW, SHIM JY, JUE DM. Dual effect of oxidative stress on NF-kappakB activation in HeLa cells. Exp Mol Med 2002; 34:332-339.
39. MACDONALD J, GALLEY HF, WEBSTER NR. Oxidative stress and gene expression in sepsis. Br J Anaesth 2003; 90:221-232.
40. VERMA IM. Nuclear factor (NF)-kappaB proteins: therapeutic targets. Ann Rheum Dis 2004; 2:57-61.
41. RUETTEN H, THIEMERMANN C. Effect of calpain inhibitor I, an inhibitor of the proteolysis of IκB, on the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat. Br J Pharmacol 1997; 121:695-704.
42. MOHAN N, SADEGHI K, REITER RJ, MELTZ ML. The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappa B. Biochem Mol Biol Int 1995; 37:1063-1070.
43. GILAD E, WONG HR, ZINGARELLI B, VIRAG L, O'CONNOR M, SALZMAN AL, SZABO C. Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NF kappa B activation. FASEB J 1998; 12:685-693.
44. SHARMA K, WANG RX, ZHANG LY et al. Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther 2000; 88:333-347.
45. DOSREIS GA, BORGES VM, ZIN WA. The central role of Fas-ligand cell signaling in inflammatory lung diseases. J Cell Mol Med 2004; 8:285-293.
46. SAYANI FA, KEENAN CM, VAN SICKLE MD et al. The expression and role of Fas ligand in intestinal inflammation. Neurogastroenterol Motil 2004; 16:61-74.
47. BAUER MK, VOGT M, LOS M, SIEGEL J, WESSELBORG S, SCHULZE-OSTHOFFM K. Role of reactive oxygen intermediates in activation-induced CD95 (APO-1/Fas) ligand expression. J Biol Chem 1998; 273:8048-8055.
48. HOHLBAUM AM, GREGORY MS, JU ST, MARSHAK-ROTHSTEIN A. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J Immunol 2001; 167:6217-6224.
49. CARTY E, DE BRABANDER M, FEAKINS RM, RAMPTON DS. Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut 2000; 46:487-492.
50. NEGORO K, KINOUCHI Y, HIWATASHI N et al. Crohn's disease is associated with novel polymorphisms in the 5′-flanking region of the tumor necrosis factor gene. Gastroenterology 1999; 17:1062-1068.
51. ANDBORN WJ, HANAUER SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999; 2:119-133.
52. URTHY S, COOPER HS, YOSHITAKE H, MEYER C, MEYER CJ, MURTHY NS. Combination therapy of pentoxifylline and TNF-α monoclonal antibody in dextran sulphate-induced mouse colitis. Aliment Pharmacol Ther 1999; 13:251-260.
53. PRESENT DH, RUTGEERTS P, TARGAN S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-1405.
54. TARGAN SR, HANAUER SB, VAN DEVENTER SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-1035.
55. VAN DULLEMEN HM, VAN DEVENTER SJ, HOMMES DW et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109:129-135.
56. RICART E, PANACCIONE R, LOFTUS EV, TREMAINE WJ, SANDBORN WJ. Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gasteroenterology 1999; 117:429-432.
57. D'HAENS G, VAN DEVENTER S, VAN HOGEZAND R et al. Endoscopic and histological healing with infliximab antitumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116:1029-1034.
58. BAERT FJ, D'HAENS GR, PEETERS M et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116:22-28.
59. MORELAND LW, MARGOLIES G, HECK LW Jr et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996; 23:1849-1855.
60. STACK WA, MANN SD, ROY AJ et al. Randomized controlled trial of CDP571 antibody to tumor necrosis factor-alpha in Crohn's disease. Lancet 1997; 349:521-524.
61. LEIST M, FAVA E, MONTECUCCO C, NICOTERA P. Peroxynitrite and nitric oxide donors induce neuronal apoptosis by eliciting autocrine excitotoxicity. Eur J Neurosci 1997; 9:1488-1498.
62. STRATER J, WELLISCH I, RIEDL S et al. CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology 1997; 113:160-167.
63. IWAMOTO M, KOJI T, MAKIYAMA K, KOBAYASHI N, NAKANE PK. Apoptosis of crypt epithelial cells in ulcerative colitis. J Pathol 1996; 180:152-159.
64. BU P, KESHAVARZIAN A, STONE DD et al. Apoptosis: one of the mechanisms that maintains unresponsiveness of the intestinal mucosal immune system. J Immunol 2001; 166:6399-6403.
65. MARQUEZ E, SANCHEZ-FIDALGO S, CALVO JR, LA DE LASTRA CA, MOTILVA V. Acutely administered melatonin is beneficial while chronic melatonin treatment aggravates the evolution of TNBS-induced colitis. J Pineal Res 2006; 40:48-55.